Background:Breast cancer is the most common malignancy in female patients. In recent years, more and more studies have focused on how to improve the appearance and the quality of life for patients. This study aimed to compare the oncologic safety, aesthetic results, and upper extremity function between single-port insufflation endoscopic nipple-sparing mastectomy (SIE-NSM) and conventional open mastectomy (C-OM) in early-stage breast cancer treatment.Methods:In our retrospective cohort, 285 patients with stage I and II breast cancer were categorized into the SIE-NSM group (n=71) and the C-OM group (n=214). We assessed local recurrence, distant metastasis, and upper extremity function across the two groups. The BREAST-Q scale was employed to analyze differences in aesthetic results, psychosocial well-being, and sexual health. The risk of local recurrence was evaluated using multivariable binary logistic regression, while a multivariable linear regression model gauged upper extremity function and aesthetic outcomes.Results:Local recurrence rates between the two groups were statistically similar (1/71, 1.4% for SIE-NSM vs. 2/214, 0.9% for C-OM, P=0.735), as confirmed by the multivariable binary logistic regression analysis. Neither group exhibited distant metastases. The SIE-NSM group demonstrated higher scores in satisfaction with breasts, chest wellness, psychosocial health, and sexual well-being (P<0.001). The SIE-NSM group also exhibited superior outcomes regarding chest wall/breast pain, shoulder mobility, and daily arm usage (P<0.001). No subcutaneous effusion was reported in the SIE-NSM group, whereas the C-OM group had a 10.7% incidence rate (P=0.004).Conclusions:SIE-NSM offers comparable oncologic safety to C-OM but provides enhanced satisfaction regarding breast appearance, physical comfort, psychosocial health, sexual health, and improved upper extremity functionality. Consequently, this innovative approach is a suitable surgical alternative for treating early-stage breast cancer.

Introduction This study compares the perioperative results, aesthetic outcome and oncologic safety of single-port insufflation endoscopic nipple-sparing subcutaneous mastectomy combined with immediate reconstruction using prosthesis implantation (SIE-NSM-IRPI) with those of conventional open-nipple and areola-sparing subcutaneous mastectomy combined with immediate reconstruction using prosthesis implantation (C-NSM-IRPI). Methods In this retrospective cohort study, 64 early-stage breast cancer patients were divided into SIE-NSM-IRPI (n = 38) and C-NSM-IRPI (n = 26) groups. Perioperative results (operation time, intraoperative blood loss, incision length, drainage duration, and recent complications) were then compared between the two groups. Differences in satisfaction with the breasts, psychosocial well-being, physical well-being (chest) and sexual well-being were analyzed according to the BREAST-Q scale, and survival outcomes were also compared. Results The median follow-up time was 51.5 months. The incision length of SIE-NSM-IRPI was shorter than that of C-NSM-IRPI ( P < 0.001). SIE-NSM-IRPI achieved the same detection rate and median number of sentinel lymph nodes as C-NSM-IRPI (3.00vs. 4.00, P = 0.780). The incidence of prosthesis removal due to infection or prosthesis exposure in the SIE-NSM-IRPI group was lower than that in the C-NSM-IRPI group ( P = 0.015). Satisfaction with breasts (82.00vs.59.00, P < 0.001), psychosocial well-being (93.00vs.77.00, P = 0.001) and physical well-being (chest) (89.00vs.82.00, P < 0.001) scores were higher in the SIE-NSM-IRPI group. There were no significant differences between the two groups in disease-free survival (hazard ratio = 0.829, 95% confidence interval = 0.182–3.779) and overall survival (hazard ratio = 1.919, 95% confidence interval = 0.169–21.842). Conclusion In this selected cohort of patients with early breast cancer, SIE-NSM-IRPI was comparable to C-NSM-IRPI, considering oncologic safety and detection of sentinel lymph nodes. It had a lower incidence of prosthesis removal, shorter incision length, and was associated with better patient satisfaction with the breasts. More random clinical trials of this novel approach in a larger cohort of Chinese patients with an extended follow-up period are needed in the future.

目的 探讨两步法单孔腔镜乳房重建手术在早期乳腺癌治疗中的临床应用价值.方法 21例早期乳腺癌患者于乳房皮下腺体切除术即刻行两步法单孔腔镜乳房重建手术;记录手术情况、术后并发症及美容效果;术后6个月,应用BREAST Q乳腺癌患者结局量表评价患者对外观满意度和生活质量.结果 21例均顺利完成两步法单孔腔镜乳房重建手术,无中转开放手术病例;术后无假体取出、包膜挛缩发生,2例发生乳头、乳晕缺血坏死,发生率为9.5％.术后6个月,BREAST Q量表评分乳房满意度为(75.3±2.2)分,胸壁状态评分为(90.4±1.5)分,社会心理状态评分为(86.1±2.0)分,性健康程度评分为(71.4±2.6)分.结论 两步法单孔腔镜乳房重建手术在早期乳腺癌治疗中应用效果良好,患者可获较好的外观满意度和生活质量.

To explore the effect of circRHOT1 on breast cancer progression and the underlying mechanism. Significantly, our data revealed that the depletion of circRHOT1 was able to repress the proliferation and induce the apoptosis of breast cancer cells. CircRHOT1 knockdown could remarkably inhibit the invasion and migration in the breast cancer cells. Meanwhile, the depletion of circRHOT1 enhanced the erastin-induced inhibition effect on cell growth of breast cancer cells. The circRHOT1 knockdown notably increased the levels of reactive oxygen species (ROS), iron, and Fe2+ in breast cancer cells. Mechanically, circRHOT1 was able to sponge microRNA-106a-5p (miR-106a-5p) and inhibited ferroptosis by down-regulating miR-106a-5p in breast cancer cells. Besides, miR-106a-5p induced ferroptosis by targeting signal transducer and activator of transcription 3 (STAT3) in the system. Moreover, the overexpression of STAT3 and miR-106a-5p inhibitor could reverse circRHOT1 knockdown-mediated breast cancer progression. Functionally, circRHOT1 promoted the tumor growth of breast cancer in vivo. In conclusion, we discovered that circRHOT1 contributed to malignant progression and attenuated ferroptosis in breast cancer by the miR-106a-5p/STAT3 axis. Our finding provides new insights into the mechanism by which circRHOT1 promotes the development of breast cancer. CircRHOT1 and miR-106a-5p may serve as potential targets for breast cancer therapy.

Objective: To examine the clinical application value of single-port inflatable endoscopic nipple sparing mastectomy with immediate reconstruction using prosthesis implantation in the treatment of early breast cancer. Methods: From February 2014 to July 2019, the clinic-pathological data of 34 early breast cancer patients received single-port inflatable endoscopic nipple sparing mastectomy with immediate reconstruction using prosthesis implantation at Department of General Surgery, Beijing Friendship Hospital, Capital Medical University were retrospectively analyzed and followed up. All the patients were female, with an age of 46(11) years (M(QR)) (range: 26 to 64 years). The radical cure degree of operation, cosmetic effect after operation were evaluated. The satisfaction to operation and personal quality of life after operation was accessed by BREAST-Q scale. Results: All surgical procedures were successfully completed. The operation time was (313.4±11.7) minutes (range: 200 to 485 minutes). The blooding-liquid was (33.8±3.3) ml (range: 10 to 100 ml). There were 5 cases (14.7%) of nipple areola necrosis after operation, of which 1 patient received taking the prosthesis out because of prosthesis exposure. There was no capsular contracture or postoperative bleeding case. The follow-up time was 35(17) months (range: 12 to 77 months), and there was one case suffering local recurrence and metastasis, and another suffering metastasis. The scores of postoperative breast satisfaction, psychosocial status, chest wall status and sexual health were 78.32±2.57 (range: 55 to 100), 89.12±2.30 (range: 82 to 100), 91.47±1.33 (range: 43 to 100), and 78.50±2.68 (range: 39 to 100). Conclusion: Single-port inflatable endoscopic nipple sparing mastectomy with immediate reconstruction using prosthesis implantation in the treatment of early breast cancer can achieve provided curative and cosmetic effect on patients with breast cancer, with good patients' postoperative quality of life and satisfaction.

Purpose To compare the oncologic safety, aesthetic outcome, and upper extremity function of single-port insufflation endoscopic nipple-sparing mastectomy (SIE-NSM) vs conventional open mastectomy (C-OM) in the treatment of early breast cancer. Methods In this retrospective cohort study, 285 stage I and II breast cancer patients were divided into the SIE-NSM group ( n = 71) and the C-OM group ( n = 214). Local recurrence, distant metastasis, and upper extremity function were compared. Differences in the aesthetic outcome, psychosocial well-being, and sexual well-being were analyzed by the BREAST-Q scale. Multivariable binary logistic regression was conducted to assess the risk of local recurrence. The multivariable linear regression model was performed to evaluate the upper extremity function and the aesthetic outcome. Results Local recurrence rates were similar ( p = 0.735), which was also shown by multivariable binary logistic regression analysis. No distant metastases were observed in either group. Satisfaction with breasts, chest well-being, psychosocial well-being, and sexual well-being scores were superior in the SIE-NSM group ( p < 0.001). Chest wall/breast pain, shoulder range of motion, and use of arm in daily life was better for the patients in the SIE-NSM group (p < 0.001). There were no cases of subcutaneous effusion in the SIE-NSM group, while the incidence rate of subcutaneous effusion in the C-OM group was 10.7% ( p = 0.004). Conclusions SIE-NSM is comparable to C-OM in oncologic safety while increasing satisfaction with breasts, physical well-being, psychosocial well-being, sexual well-being, and upper extremity function. This novel method is an appropriate surgical option for early breast cancer treatment.

乳腺癌术后即刻乳房重建越来越多地被应用于临床.根据填充使用的内容物,乳房重建可以分为假体乳房重建与自体组织乳房重建手术[1-4].假体置入乳房重建手术存在费用高昂的问题;另外,为了形成充分包裹与托持、使乳房下极呈现一定垂度,常需要联合脱细胞异体真皮等人工材料,该方法已被证实会导致血清肿、假体取出、红色征等并发症的增加[4-5].自体组织乳房重建最常用的有背阔肌皮瓣、腹直肌皮瓣、腹壁下动脉穿支皮瓣等,但这些皮瓣均存在供区创伤较大、血管危象不易处理等问题[3,5].

The aim of the present research work was to investigate the anti-cancer and apoptotic effects of bergaptol in human breast cancer cells (MCF-7). The effects on cell cycle arrest and caspase activation were evaluated. MTT assay was used to evaluate the effect of the compound on cell viability. Cellular morphology was demonstrated by fluorescence microscopy. Flow cytometry was used to analyze effect of bergaptol on cell cycle and apoptosis. The results revealed that bergaptol induced dose-dependent cytotoxic effect on MCF-7 cell viability showing IC 50 value of 52.2 µM. Bergaptol induced both early and late apoptosis in concentration-dependent manner. After treatment with bergaptol, an increase in the proportion of cells in the S-phase (37.2, 45.3 and 65.1% as compared to 28.6% in untreated cells) and a reduction in the fraction of cells in the G1 phase (44.1, 41.6 and 35.2% as compared to 51.2% in the untreated cells) was observed.

Background and ObjectivesTo evaluate efficacy and aesthetic outcome for combined endoscopic subcutaneous mastectomy (E‐SM) and endoscopic sentinel lymph node biopsy (E‐SLNB) in early stage breast cancer patients.MethodsCombined E‐SM+E‐SLNB was compared to modified radical resection in a cohort of Chinese patients (n = 49) with stages I and II breast cancer. Patient satisfaction with the aesthetic results was assessed 1 year after surgery with a 5‐item‐by‐4‐step scoring system for evaluating cosmetic outcomes.ResultsAll patients were alive 1 year following surgery with no locoregional recurrence or distant metastases and without any critical complications. The average length of incision was less in patients receiving E‐SM+E‐SLNB (4.4 vs. 19.4 cm; P < 0.001), but time in surgery was longer (131.6 vs. 99.2 min; P = 0.024). After 1 year, nearly all E‐SM+E‐SLNB patients rated satisfaction with their appearance as excellent or good (23/24; 95.8% vs. 19/25; 76.0%; P < 0.001), and exhibited less disturbance of sensory (P < 0.001) and motor function (P = 0.014) relative to modified radical resection.ConclusionsE‐SM+E‐SLNB provides significant aesthetic and functional advantages for patients with early stage breast cancer without compromising medical efficacy as assessed at 16 months postsurgery. J. Surg. Oncol. 2016;113:616–620. © 2016 Wiley Periodicals, Inc.

The expression of taxol resistance gene 1 and thrombospondin 1 remains unknown in human breast cancer tissues. In the current study, we sought to measure the mRNA expression levels of taxol resistance gene 1 and thrombospondin 1 in breast cancer tissue and adjacent normal tissue specimens and further analyzed their expression according to the molecular subtypes and age of breast cancer patients who had received taxane-containing regimens. Archived breast cancer and adjacent non-tumor tissue specimens were obtained at Beijing Friendship Hospital, Beijing, China. The mRNA transcript levels of taxol resistance gene 1, thrombospondin 1 and multi-drug resistance 1 were determined by quantitative RT-PCR. Taxol resistance gene 1 and multi-drug resistance 1 protein levels were measured by immunoblotting assays. Forty-nine archived breast cancer tissue specimens were included. The majority of the specimens (65.3%) were of the molecular subtype A followed by triple negative breast cancer (14.3%). The mRNA transcript levels of taxol resistance gene 1 , thrombospondin 1 and multi-drug resistance 1 in breast cancer tissues were higher than those of adjacent normal tissues. The mRNA expression of TXR1 in the HER2 subtype (4.513 ± 0.810) was the highest and in the Luminal B subtype was the lowest (3.103 ± 0.417) among the four molecular subtypes. The HER2 subtype also had the highest mRNA expression of thrombospondin 1(4.827 ± 0.927) and the Luminal B subtype had the lowest TSP1 mRNA level (3.197 ± 0.565) among the four molecular subtypes. Our study represents the first attempt in delineating taxol resistance gene 1 and thrombospondin 1 expression in breast cancer and we demonstrate that taxol resistance gene 1 and thrombospondin 1 expression may vary according to the molecular subtypes of breast cancer.

1 临床资料患者女,28岁.因皮肤、巩膜黄染10 d,于2012年4月17日入院.患者10 d前无明显诱因出现皮肤、巩膜黄染,伴皮肤瘙痒、尿色黄染及大便颜色变浅.于外院保守治疗后黄疸逐渐消退.自发病以来无腹痛、发热、盗汗、咳嗽等不适,无消瘦.既往无结核病史或接触史.体格检查:体温36.5℃;右侧颈部可触及一直径约2 cm包块,质地坚韧,活动度小,无压痛;双肺呼吸音清,未闻及干湿啰音;皮肤、巩膜轻度黄染,无抓痕;腹软,无揉面感,全腹无压痛、反跳痛或肌紧张,右季肋区可触及胆囊下缘,无触痛,肝脾肋下未触及. 关键词：淋巴结结核;腹腔;囊性肿瘤